Paper26316700
RGD-modified liposomes enhance efficiency of aclacinomycin A delivery: evaluation of their effect in lung cancer.
Feng C and 5 others. Drug Des Devel Ther, 2015. Cited by 11 papers, by iCite.
Cite this record
ConductScience Library. RGD-modified liposomes enhance efficiency of aclacinomycin A delivery: evaluation of their effect in lung cancer. Papers, record 26316700. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26316700
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- RGD-modified liposomes enhance efficiency of aclacinomycin A delivery: evaluation of their effect in lung cancer.
- PubMed
Topics23
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Aclarubicin | Major topic |
| Adenocarcinoma | Major topic |
| Antibiotics, Antineoplastic | Major topic |
| Lipids | Major topic |
| Lung Neoplasms | Major topic |
| Oligopeptides | Major topic |
| Adenocarcinoma of Lung | |
| Animals | |
| Area Under Curve | |
| Cell Line, Tumor | |
| Chemistry, Pharmaceutical | |
| Delayed-Action Preparations | |
| Drug Stability | |
| Half-Life | |
| Injections, Intravenous | |
| Liposomes | |
| Mice, Inbred BALB C | |
| Mice, Nude | |
| Particle Size | |
| Rats | |
| Solubility | |
| Tumor Burden | |
| Xenograft Model Antitumor Assays |
Source PubMed
References23
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22490676 | Antibodies causing thrombocytopenia in patients treated with RGD-mimetic platelet inhibitors recognize ligand-specific conformers of αIIb/β3 integrin. | Blood | 2012 | https://conductscience.org/library/papers/22490676 | PubMed |
| 2 | 8970741 | RGD and other recognition sequences for integrins. | Annu Rev Cell Dev Biol | 1996 | https://conductscience.org/library/papers/8970741 | PubMed |
| 3 | 22888235 | Cyclic RGD peptide-modified liposomal drug delivery system: enhanced cellular uptake in vitro and improved pharmacokinetics in rats. | Int J Nanomedicine | 2012 | https://conductscience.org/library/papers/22888235 | PubMed |
| 4 | 22967287 | RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. | Mol Pharm | 2012 | https://conductscience.org/library/papers/22967287 | PubMed |
| 5 | 23973508 | Effects of mycophenolic acid-glucosamine conjugates on the base of kidney targeted drug delivery. | Int J Pharm | 2013 | https://conductscience.org/library/papers/23973508 | PubMed |
| 6 | 23959851 | Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases. | Pharm Res | 2013 | https://conductscience.org/library/papers/23959851 | PubMed |
| 7 | 23957267 | Liposomes in drug delivery: a patent review (2007 - present). | Expert Opin Ther Pat | 2013 | https://conductscience.org/library/papers/23957267 | PubMed |
| 8 | 23979293 | Synthesis of VIP-lipopeptide using a new linker to modify liposomes: towards the development of a drug delivery system for active targeting. | Chem Pharm Bull (Tokyo) | 2013 | https://conductscience.org/library/papers/23979293 | PubMed |
| 9 | 24070211 | Bone regeneration potential of stem cells derived from periodontal ligament or gingival tissue sources encapsulated in RGD-modified alginate scaffold. | Tissue Eng Part A | 2014 | https://conductscience.org/library/papers/24070211 | PubMed |
| 10 | 24611009 | GE11-modified liposomes for non-small cell lung cancer targeting: preparation, ex vitro and in vivo evaluation. | Int J Nanomedicine | 2014 | https://conductscience.org/library/papers/24611009 | PubMed |
| 11 | 25371296 | Formulation, characterization, and in vitro/vivo studies of aclacinomycin A-loaded solid lipid nanoparticles. | Drug Deliv | 2016 | https://conductscience.org/library/papers/25371296 | PubMed |
| 12 | 11948551 | Antitumor effects and pharmacokinetics of aclacinomycin A carried by injectable emulsions composed of vitamin E, cholesterol, and PEG-lipid. | J Pharm Sci | 2002 | https://conductscience.org/library/papers/11948551 | PubMed |
| 13 | 12234975 | Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. | Cancer Res | 2002 | https://conductscience.org/library/papers/12234975 | PubMed |
| 14 | 12470989 | Probing the structural and molecular diversity of tumor vasculature. | Trends Mol Med | 2002 | https://conductscience.org/library/papers/12470989 | PubMed |
| 15 | 12516034 | Role of angiogenesis in tumor growth and metastasis. | Semin Oncol | 2002 | https://conductscience.org/library/papers/12516034 | PubMed |
| 16 | 9377570 | Aclacinomycin A stabilizes topoisomerase I covalent complexes. | Cancer Res | 1997 | https://conductscience.org/library/papers/9377570 | PubMed |
| 17 | 9359101 | On target with tumor blood vessel markers. | Nat Biotechnol | 1997 | https://conductscience.org/library/papers/9359101 | PubMed |
| 18 | 17896915 | Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers. | Anticancer Agents Med Chem | 2007 | https://conductscience.org/library/papers/17896915 | PubMed |
| 19 | 17826969 | Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. | Eur J Pharm Biopharm | 2008 | https://conductscience.org/library/papers/17826969 | PubMed |
| 20 | 21475772 | A novel family of RGD-containing disintegrins (Tablysin-15) from the salivary gland of the horsefly Tabanus yao targets αIIbβ3 or αVβ3 and inhibits platelet aggregation and angiogenesis. | Thromb Haemost | 2011 | https://conductscience.org/library/papers/21475772 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40051630 | Aclacinomycin enhances the killing effect of allogeneic NK cells on acute myeloid leukemia cells by inducing immunogenic cell death. | Front Immunol | 2025 | https://conductscience.org/library/papers/40051630 | PubMed |
| 36985733 | Rethinking Biosynthesis of Aclacinomycin A. | Molecules | 2023 | https://conductscience.org/library/papers/36985733 | PubMed |
| 29075099 | Design and evaluation of lidocaine- and prilocaine-coloaded nanoparticulate drug delivery systems for topical anesthetic analgesic therapy: a comparison between solid lipid nanoparticles and nanostructured lipid carriers. | Drug Des Devel Ther | 2017 | https://conductscience.org/library/papers/29075099 | PubMed |
| 28721013 | A novel local anesthetic system: transcriptional transactivator peptide-decorated nanocarriers for skin delivery of ropivacaine. | Drug Des Devel Ther | 2017 | https://conductscience.org/library/papers/28721013 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| FGB | 2244 | PubTator's text mining | https://conductscience.org/library/genes/2244 | NCBI Gene |
| VTN | 7448 | PubTator's text mining | https://conductscience.org/library/genes/7448 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/26316700
GET https://conductscience.org/api/papers/v1/26316700/references?page=2